Payment overview · 2025
General Payments
$527.77
22 reported records · 9 companies
Healthcare provider profile · identity verified
Aaron M Fields, DO
Allopathic & Osteopathic Physicians|Family Medicine · PUEBLO, CO · NPI 1922061522
Verified facts
What the public records show
CMS Open Payments records show Aaron M Fields, DO received $527.77 in general payments during 2025 across 22 reported records.
InspireMD Ltd accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| InspireMD Ltd | Unresolved — no canonical attribution shown | $142.86 | 27.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.16 | 16.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.78 | 14.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.15 | 13.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.46 | 9.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.22 | 6.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.86 | 5.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.04 | 3.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.24 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $527.77 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $142.86 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.19 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.37 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.46 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $51.46 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.05 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.09 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.86 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 117 |
| Lisinopril | Lisinopril | 294 | 86 |
| Omeprazole | Omeprazole | 262 | 74 |
| Losartan Potassium | Losartan Potassium | 259 | 78 |
| Tramadol Hcl | Tramadol Hcl | 236 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 64 |
| Gabapentin | Gabapentin | 232 | 58 |
| Quetiapine Fumarate | Quetiapine Fumarate | 225 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 43 |
| Metformin Hcl | Metformin Hcl | 122 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 19 |
| Simvastatin | Simvastatin | 112 | 30 |
| Potassium Chloride | Potassium Chloride | 110 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 36 |
| Meloxicam | Meloxicam | 102 | 31 |
| Furosemide | Furosemide | 101 | 35 |
| Clonazepam | Clonazepam | 93 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 30 |
| Azithromycin | Azithromycin | 83 | 62 |
| Diazepam | Diazepam | 80 | 12 |
| Eliquis | Apixaban | 78 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 71 | 27 |
| Metformin Hcl Er | Metformin Hcl | 70 | 20 |
| Montelukast Sodium | Montelukast Sodium | 69 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 22 |
| Ozempic | Semaglutide | 68 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 19 |
| Trazodone Hcl | Trazodone Hcl | 67 | 18 |
| Atenolol | Atenolol | 66 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 64 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 15 |
| Finasteride | Finasteride | 61 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 23 |
| Xarelto | Rivaroxaban | 59 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Repatha Sureclick | Evolocumab | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 13 |
| Carvedilol | Carvedilol | 49 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 16 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 15 |
| Ibuprofen | Ibuprofen | 44 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Temazepam | Temazepam | 43 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 29 |
| Spironolactone | Spironolactone | 41 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Prednisone | Prednisone | 40 | 25 |
| Trulicity | Dulaglutide | 40 | 11 |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 15 |
| Celecoxib | Celecoxib | 37 | 17 |
| Famotidine | Famotidine | 37 | 16 |
| Vascepa | Icosapent Ethyl | 36 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 13 |
| Mupirocin | Mupirocin | 30 | 21 |
| Allopurinol | Allopurinol | 29 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Tadalafil | Tadalafil | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 15 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 16 |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $527.77 · 22 records | InspireMD Ltd | AIRSUPRA, AREXVY, CGuard Prime Carotid Stent System, Cologuard Collection Kit, Dexcom G6 Transmitter, GEMTESA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error